A review of the regulatory framework for personalized bacteriophages registration
- Authors: Landyshev N.N.1, Voronko Y.G.1, Timoshina O.Y.2,3, Suslina S.N.1, Akimkin V.G.3, Miroshnikov K.A.2
-
Affiliations:
- Institute of Medicine, RUDN University
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences
- Central Research Institute for Epidemiology of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare
- Issue: Vol 65, No 5 (2020)
- Pages: 259-266
- Section: REVIEWS
- URL: https://journals.rcsi.science/0507-4088/article/view/118132
- DOI: https://doi.org/10.36233/0507-4088-2020-65-5-2
- ID: 118132
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
N. N. Landyshev
Institute of Medicine, RUDN University
Email: fake@neicon.ru
ORCID iD: 0000-0002-9289-6849
PhD student, Institute of Medicine
Moscow, 117198
Russian FederationYa. G. Voronko
Institute of Medicine, RUDN University
Email: fake@neicon.ru
ORCID iD: 0000-0003-0779-5742
Specialist student, Institute of Medicine
Moscow, 117198
Russian FederationO. Yu. Timoshina
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences;Central Research Institute for Epidemiology of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare
Email: fake@neicon.ru
ORCID iD: 0000-0001-8727-9734
junior researcher, Laboratory of molecular bioengineering; researcher, Laboratory for molecular diagnostics and epidemiology of reproductive tract infections
Moscow, 117997
Moscow, 111123
Russian FederationS. N. Suslina
Institute of Medicine, RUDN University
Email: fake@neicon.ru
PhD (Pharmacy), Associate Professor, Head of the division of General pharmaceutical and biomedical technology
Moscow, 117198
Russian FederationV. G. Akimkin
Central Research Institute for Epidemiology of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare
Email: fake@neicon.ru
ORCID iD: 0000-0003-4228-9044
academician of RAS, D. Sci. (Med.), prof., Head
Moscow, 111123
Russian FederationK. A. Miroshnikov
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences
Author for correspondence.
Email: kmi@ibch.ru
ORCID iD: 0000-0002-4468-4091
D.Sci. (Chem.), Major research associate, Head of Laboratory of molecular bioengineering
Moscow, 117997
Russian FederationReferences
- Fleming A. Penicillin. Nobel lectures, physiology or medicine 1942–1962. Amsterdam, NL: Elsevier Publishing; 1964.
- O’Neill J. Tackling drug-resistant infections globally: Final report and recommendations. London: HM Government and Welcome Trust; 2018.
- Cisek A.A., Dąbrowska I., Gregorczyk K.P., Wyżewski Z. Phage therapy in bacterial infections treatment: one hundred years after the discovery of bacteriophages. Curr. Microbiol. 2017; 74(2): 277–83. https://doi.org/10.1007/s00284-016-1166-x
- International Monetary Fund. World Economic Outlook: Global Manufacturing Downturn, Rising Trade Barriers. Washington: International Monetary Fund, Publication Services; 2019.
- Pirnay J.P., De Vos D., Verbeken G., Merabishvili M., Chanishvili N., Vaneechoutte M., et al. The phage therapy paradigm: Prêt-à-porter or sur-mesure? Pharm. Res. 2011; 28(4): 934–7. https://doi.org/10.1007/s11095-010-0313-5
- McCallin S., Oechslin F. Bacterial resistance to phage and its impact on clinical therapy. In: Górski A., Międzybrodzki R., Borysowski J., eds. Phage Therapy: A Practical Approach. Cham: Springer International Publishing; 2019: 59–88.
- Oechslin F. Resistance development to bacteriophages occurring during bacteriophage therapy. Viruses. 2018; 10(7): 351. https://doi.org/10.3390/v10070351
- Van Belleghem J.D., Dąbrowska K., Vaneechoutte M., Barr J.J., Bollyky P.L. Interactions between bacteriophage, bacteria, and the mammalian immune system. Viruses. 2019; 11(1): 10. https://doi.org/10.3390/v11010010
- Hodyra-Stefaniak K., Miernikiewicz P., Drapała J., Drab M., Jonczyk-Matysiak E., Lecion D., et al. Mammalian Host- VersusPhage immune response determines phage fate in vivo. Sci. Rep. 2015; 5: 14802. https://doi.org/10.1038/srep14802
- Fauconnier A. Phage therapy regulation: From night to dawn. Viruses. 2019; 11(4): 352. https://doi.org/10.3390/v11040352
- Sullivan T. A tough road: cost to develop one new drug is $2.6 billion; approval rate for drugs entering clinical development is less than 12%. Policy and Medicine. 2019. Available at: https://www.policymed.com/2014/12/a-tough-road-cost-to-develop-one-new-drugis-26-billion-approval-rate-for-drugs-entering-clinical-de.html
- Todd K. The promising viral threat to bacterial resistance: The uncertain patentability of phage therapeutics and the necessity of alternative incentives. Duke Law J. 2018; 68(4): 767–805.
- Mossialos E., Ge Y., Hu J., Wang L. Pharmaceutical Policy in China Challenges and Opportunities for Reform. Copenhagen: WHO; 2016: 1–212.
- Wu J.Z., Hsu Y.C. Decision analysis on entering the China pharmaceutical market: Perspectives from Taiwanese companies. Comput. Ind. Eng. 2018; 125: 751–63. https://doi.org/10.1016/j.cie.2018.05.054
- de Souza Rp., Guedes H. The compounding pharmacy in Brazil: A pharmacist’s perspective. Int. J. Pharm. Compd. 2009; 13(1): 87–8.
- Bertoldi A.D., Wagner A.K., Emmerick I.C.M., Chaves L.A., Stephens P., Ross-Degnan D. The Brazilian private pharmaceutical market after the first ten years of the generics law. J. Pharm. Policy Pract. 2019; 12: 18. https://doi.org/10.1186/s40545-019-0179-9
- McCallin S., Sacher J.C., Zheng J., Chan B.K. Current state of compassionate phage therapy. Viruses. 2019; 11(4): 343. https://doi.org/10.3390/v11040343
- Slater J.E., Menzies S.L., Bridgewater J., Mosquera A., Zinderman C.E., Ou A.C., et al. The US Food and Drug Administration review of the safety and effectiveness of nonstandardized allergen extracts. J. Allergy Clin. Immunol. 2012; 129(4): 1014–9. https://doi.org/10.1016/j.jaci.2012.01.066
- Gandesiri S., Srujana M.P., Reddy Y.P., Rathinavelu M. Assessment of knowledge, attitude and perception towards good pharmacy practice in community pharmacists of India. World J. Pharm. Res. 2015; 4990(5): 1738–46.
- Huys I., Pirnay J.P., Lavigne R., Jennes S., De Vos D., Casteels M., et al. Paving a regulatory pathway for phage therapy. Europe should muster the resources to financially, technically and legally support the introduction of phage therapy. EMBO Rep. 2013; 14(11): 951–4. https://doi.org/10.1038/embor.2013.163
- Henein A. What are the limitations on the wider therapeutic use of phage? Bacteriophage. 2013; 3(2): e24872. https://doi.org/10.4161/bact.24872
- Scheepers H.P.A., Langedijk J., Neerup Handlos V., Walser S., Schutjens M.H., Neef C. Legislation on the preparation of medicinal products in European pharmacies and the Council of Europe Resolution. Eur. J. Hosp. Pharm. 2017; 24(4): 224–9. https://doi.org/10.1136/ejhpharm-2016-001016
- Pirnay J.P., Verbeken G., Ceyssens P.J., Huys I., de Vos D., Ameloot C., et al. The magistral phage. Viruses. 2018; 10(2): 64. https://doi.org/10.3390/v10020064